|
|
Post by roguesuerte on Mar 5, 2017 23:29:41 GMT -5
I have always appreciated your optimism rancho and your posts,but I cant see how we are are now on a new path. Management seems to have a total disregard for shareholders and a total lack of transparency. We have no media exposure for Afrezza and script numbers that forecast our imminent demise. If the nefarious interests that be took this from roughly 6.50 when I started buying down to 50 cents, how hard will it be for them to take it back down at 2 bucks and change to uner a dollar if the piss poor scripts continue. These new reps are "cold calling" on doctors, without advertising. Many of these docs never heard of Afrezza, or think it was taken off the market,so how do we succeed without advertising?
|
|
|
|
Post by sportsrancho on Mar 5, 2017 23:54:03 GMT -5
I agree, I have never been a fan of calling on the Endo's. Although I know it's part of the process. I have always said, " tell the people" . I believe that is what is going to start happening. And when that happens and we have a demand the reps will be there to help.
There is nothing I hate more than a RS except a delisted stock. I'm sick about it. But if I think about it to much I won't be able to be a good spokesperson for Afrezza. I guess that's my point:-)
I wish all of you so much good luck, it's a race against time but I do think Mike has been very busy:-)
|
|
|
|
Post by minnlearner on Mar 6, 2017 0:31:28 GMT -5
Sports, I like your positive. I always think " You see what you look for" So I try to look and do for the good. I will be made fun of by the 'smart investors' but I can live with myself. I like your posts. Thanks.
|
|
|
|
Post by silentknight on Mar 6, 2017 7:01:56 GMT -5
There has to be a two pronged approach. MNKD will have to simultaneously educate prescribers on the merits of Afrezza while also informing diabetics that Afrezza exists as an option for them. Quite frankly, MNKD has failed on both fronts so far which is why you've seen laughable script numbers every week.
Doctors have proven to be unwilling to write scripts for Afrezza. Why? It could be that they are generally risk-averse to a new drug, but I also believe that it's because there has been little to no effort by sales personnel to get the drug prescribed. I realize this may be a difficult task and easier said than done, but seeing 200-250 scripts per week nationwide is pathetic by any standard. Sanofi at one point was seeing 600 scripts per week if I'm not mistaken, and the trend appeared to be positive until they likely decided that Afrezza wasn't meeting expectations and decided to pull the plug, at which point all efforts to sell Afrezza stopped. They waited until the first available option to terminate the partnership and did so. But seeing how things can go, there's no reason to believe that a sales force that's any good at all can't achieve similar results. It will take better communication than we've seen thus far and it will be incumbent on the sales team to convince doctors that the product is better than the label says it is. Perhaps a label change will help with this, but that's going to be several months away and MNKD doesn't have that long. The sales team also has to do a better job in explaining titration to physicians to ensure patient retention. Bottom line: the sales team has to deliver.
For patients, we've seen pretty anemic attempts by MNKD to inform the public that the product even exists. Mike said on the call that 9 out of 10 people are completely unaware of Afrezza at all. There has to be more than JDRF walks and paper inserts into football programs that nobody reads. A for effort but F on results. It has proven to be worthless. There has to be well-crafted and appealing nationwide commercials to inform the public that there is a needle-free option. Thankfully, this too is in the works but time is of the essence. It needed to happen yesterday. Yes, commercials would be better served with a new label if that ever occurs, but once again, MNKD cannot afford to wait. Bottom line: the commercial team (Mike) needs to deliver.
The two are symbiotic. Both must exist for Afrezza to be a success. To date, MNKD has failed miserably on both but I believe they are actually devoting time and resources into giving Afrezza a chance.
Make no mistake about it. If Afrezza doesn't succeed within the next year, assuming MNKD can find a way to stay alive that long, then MNKD will have demonstrated themselves to be completely incapable of doing it at all, which does not bode well for Epi or any other future product, or the company in general.
|
|
|
|
Post by saxcmann on Mar 6, 2017 8:37:42 GMT -5
There has to be a two pronged approach. MNKD will have to simultaneously educate prescribers on the merits of Afrezza while also informing diabetics that Afrezza exists as an option for them. Quite frankly, MNKD has failed on both fronts so far which is why you've seen laughable script numbers every week. Doctors have proven to be unwilling to write scripts for Afrezza. Why? It could be that they are generally risk-averse to a new drug, but I also believe that it's because there has been little to no effort by sales personnel to get the drug prescribed. I realize this may be a difficult task and easier said than done, but seeing 200-250 scripts per week nationwide is pathetic by any standard. Sanofi at one point was seeing 600 scripts per week if I'm not mistaken, and the trend appeared to be positive until they likely decided that Afrezza wasn't meeting expectations and decided to pull the plug, at which point all efforts to sell Afrezza stopped. They waited until the first available option to terminate the partnership and did so. But seeing how things can go, there's no reason to believe that a sales force that's any good at all can't achieve similar results. It will take better communication than we've seen thus far and it will be incumbent on the sales team to convince doctors that the product is better than the label says it is. Perhaps a label change will help with this, but that's going to be several months away and MNKD doesn't have that long. The sales team also has to do a better job in explaining titration to physicians to ensure patient retention. Bottom line: the sales team has to deliver. For patients, we've seen pretty anemic attempts by MNKD to inform the public that the product even exists. Mike said on the call that 9 out of 10 people are completely unaware of Afrezza at all. There has to be more than JDRF walks and paper inserts into football programs that nobody reads. A for effort but F on results. It has proven to be worthless. There has to be well-crafted and appealing nationwide commercials to inform the public that there is a needle-free option. Thankfully, this too is in the works but time is of the essence. It needed to happen yesterday. Yes, commercials would be better served with a new label if that ever occurs, but once again, MNKD cannot afford to wait. Bottom line: the commercial team (Mike) needs to deliver. The two are symbiotic. Both must exist for Afrezza to be a success. To date, MNKD has failed miserably on both but I believe they are actually devoting time and resources into giving Afrezza a chance. Make no mistake about it. If Afrezza doesn't succeed within the next year, assuming MNKD can find a way to stay alive that long, then MNKD will have demonstrated themselves to be completely incapable of doing it at all, which does not bode well for Epi or any other future product, or the company in general. Good post knight. I agree mostly. Not sure they have a few years? Scripts need to get close to Sanofi numbers and things will turn. |
|
|
|
Post by Cowgirl on Mar 6, 2017 9:38:14 GMT -5
"The commercial team needs to deliver"...
With lack of awareness, no adds, insurance issues, being brand new etc...it won't happen in any quick order. We are out of money in a few months.
What needs to happen is a portion of MNKD equity needs to be sold to a large investor. Al Mann's Foundation needs to unload a piece (and it will be cheap) so that someone out there has a chance to do something with Afrezza. Right now it's locked up by almost majority ownership yet we have no money. MNKD has trapped itself.
|
|
|
|
Post by lojothehus on Mar 6, 2017 11:56:54 GMT -5
I'm fighting back the only way I know how. All this bitching, it is what is is. And sometimes good for the soul. I did a lot of bitching about those other reps. But we are on a new path. The only thing we can do is put one foot in front of the other. Tell someone about Afrezza when ever we get the chance. Support Matt and Mike and our new sales team! What do we have to lose? It's your money! The intention is not to bash Matt or Mike, but to move them into action. You said it yourself, "tell someone about Afrezza when ever we get the chance." Well they have the platform and they need to use it in a non-traditional way. Look at the MNKD Website when you get a chance. There should be newsworthy posts on that website every day! They should be talking Afrezza everyday. There should be pictures of needles and pin cushions. They should cater the site to diabetics who are looking for a better treatment as opposed to doctors and endos. Talk, talk, advertise, advertise, go to the news stations, put the links to the coverage that you already have on your website. Create a page for testimonials. Create a chat page for the few who are using it. C'mon Sportsrancho, c'mon Matt, c'mon Mike give me a fraction of the money that you guys are spending and we can get this in the ears of the common diabetic! |
|
|
|
Post by peppy on Mar 6, 2017 12:02:03 GMT -5
here is the problem. we get the news to the common diabetic and their physicians says no.
sweedee dad, aged, etc.
Although the better connected seem to be able to get it. Laura K. sam, eric, Lauren
|
|
|
|
Post by lojothehus on Mar 6, 2017 12:15:39 GMT -5
here is the problem. we get the news to the common diabetic and their physicians says no.
sweedee dad, aged, etc.
Although the better connected seem to be able to get it. Laura K. sam, eric, Lauren
Then they go to a physician who will and after a few of those, the doctors will say yes. |
|
